Posted by Michael Wonder on 06 Jan 2018
Veltassa approved for marketing in Switzerland for the treatment of hyperkalaemia
3 January 2018 - SwissMedic has approved patiromer to be marketed in Switzerland as Veltassa for the treatment of hyoperkalaemia in adults.
Veltassa is a sodium-free potassium binder approved for the treatment of hyperkalaemia in adults. This therapy can also be made available to patients who develop hyperkalaemia while being treated with drugs inhibiting the renin-angiotensin-aldosterone system, including e.g. angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and aldosterone antagonists, which are often used to treat hypertension or heart failure. Nearly all patients treated with Veltassa in the phase II-III clinical programme were on renin angiotensin aldosterone system inhibitors (RAASi) at baseline. Veltassa is expected to be available for patients during the first half year of 2018.
